RELATED: Number of fentanyl deaths in Minnesota increased in 2017
The FDA also said that subsys "should only be used by oncologists and pain specialists with experience in the treatment of cancer pain," according to the publication.
"To enrich the balance, the company encouraged physicians to prescribe this highly potent fentanyl supplement to patients who did not have cancer, although it was only approved for severe breakthrough pain in cancer patients," said Swanson.
The lawsuit alleges Insys commits a rate of one or more new subscriptions per day to its sales representatives. To increase sales, Insys allegedly advertised subscriptions for off-label applications and higher dosages and looked for doctors willing to prescribe the drug to non-cancer patients.
Advice: Opioids in Minnesota [1
Materials subsys provided to physicians said 75% of patients found effective SUBSYS between 600 and 1600 [micrograms] and "only 4% of patients reported over 100 [micrograms] as an effective dose," states the press release. The sales department of Insys received $ 340 a quarter for every 100 micrograms prescription, but 2,532 a quarter for 1,200 micrograms prescriptions, the lawsuit states.
According to the lawsuit, a sales executive told Insys' vice president that a Minnesota doctor was "afraid to prescribe the painkiller and wanted" no reason for the DEA to come after him.
RELATED APPLICATION: Dayton Adopts New Guidelines on Opioid Dependence
The Vice President responded, "Stop using the excuses and start solving," claims the lawsuit.
Following the release, Insys paid two Minnesota dues. Physicians gave more than $ 43,000 for lectures and these physicians later became the top subscribers to the Minnesota company, claiming that some of these events were fronts involving only a sales agent or a staff member of the doctor, and that payments were an incentive Doctors were used to prescribe subsys.
Several Insys executives, including the former vice president of sales and former CEO, were recruited by the US-A nwalt in Massachusetts for the role in the marketing of subsidies accused after publication.
RELATED: "It's disgraceful": Dayton responds to KSTP investigation thousands of minn. Doctors find breaking law
The release also states that the Minnesota Board of Medical Practice entered into an agreement with a medical assistant for the prescription of excessive doses of subsys. Insy's sales agents visited this assistant 16 times, during which time she wrote 52 subsys recipes, according to the publication.
"By promoting the off-label use of a strong opioid and making inappropriate payments to prescribers, Insys has broken the law and endangers public health, and it's imperative that medicines be properly prescribed," said Cody Wiberg , Executive Director of the Minnesota Board of Pharmacy. "Consequently, it's important to ensure that Insys is held accountable for his actions."
CONVICTION: Thousands of Minn. Doctors break the law by not registering for prescription surveillance programs
Fentanyl is a synthetic opioid 50 times more potent than heroin. In 2017, Fentanyl contributed to the death of 156 people in Minnesota.